Roche signs $5.3 billion deal with Danish obesity drugmaker, Novo stock slides 4%
Roche (RHHBY) is increasing its investment into the obesity space with an up to $5.3 billion deal with Danish drugmaker Zealand Pharma (ZLDPF), the companies announced Wednesday. The deal would give Zealand a partner to co-develop petrelintide,
Roche-Zealand deal is the latest to boost obesity space
Shares of weight loss drug developers gained on Wednesday after Roche (OTCQX:RHHBF) announced a multi-billion-dollar deal with Danish biotech Zealand Pharma (OTCPK:ZLDPF) to jointly develop an obesity therapy,
Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal
Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion under an agreement to co-develop a weight-loss treatment.
Roche secures Zealand obesity drug candidate for up to $5.3 billion
Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, as the Swiss drugmaker seeks to boost its prospects in the booming weight-loss market.
Roche signs biggest-ever obesity drug deal
Roche has signed the biggest-ever obesity drug deal with a $5.3bn licensing agreement for a next-generation treatment from Danish biotech Zealand Pharma. The Swiss pharmaceutical company will collaborate with Zealand on petrelintide,
Roche, Zealand Pharma in $5.3 Billion Pact for Obesity Drugs
Roche Holding AG licensed a new weight-loss drug from Zealand Pharma A/S for as much as $5.3 billion, bolstering the Swiss drugmaker’s effort to get into a hot market dominated by Novo Nordisk A/S and Eli Lilly & Co.
Roche pairs with Zealand Pharma on obesity drug candidate
Roche has entered an exclusive collaboration and licensing agreement with Danish obesity drug maker Zealand Pharma to co-develop petrelintide as an obesity therapy drug, the Swiss company said on Wednesday.
Zealand Pharma upgraded to Buy from Hold at SEB Equities
SEB Equities upgraded Zealand Pharma (ZLDPF) to Buy from Hold with an DKK 850 price target Light Up your Portfolio with Spark:Easily identify ...
Benzinga.com1y
Zealand Pharma Stock Price, Quotes and Forecasts | OTC:ZLDPF | Benzinga
Stay updated on market trends for ZLDPF. Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names The $200B GLP-1 market ...
Seeking Alpha21d
Zealand Pharma A/S (ZLDPF) Q4 2024 Earnings Call Transcript
Welcome to the Zealand Pharma Results for Full Year 2024 Conference Call. [Operator Instructions]. I would now like to hand the conference over to your speaker today Anna Krassowska, Head of ...
Zealand Pharma to pay $350M to Roche in petrelintide collaboration, license pact
Zealand Pharma (ZLDPF) and Roche (RHHBY) entered a collaboration and license agreement to co-develop and co-commercialize petrelintide as a ...
Yahoo Finance21d
Zealand Pharma AS (ZLDPF) Q4 2024 Earnings Call Highlights: Strong Cash Position and Obesity ...
Zealand Pharma AS (ZLDPF) reported significant clinical advancements in their obesity pipeline, particularly with petrelintide and survodutide. The company has a strong cash position of DKK9 ...
ETF Daily News27d
Zealand Pharma A/S (OTCMKTS:ZLDPF) Sees Large Increase in Short Interest
OTCMKTS:ZLDPF opened at $104.01 on Friday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 35.49 and a current ratio of 35.49. Zealand Pharma A/S has a 52-week low of $67.58 and a ...
Morningstar14d
Zealand Pharma AS ZLDPF
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...